Biogen Turns To Plegridy As Avonex Sales Wane
This article was originally published in The Pink Sheet Daily
Executive Summary
The MS powerhouse got approval for its fourth treatment for the disease; the drug will help bolster the franchise while sales of some of the other drugs are eroded.